# Ethyl Icosapentate and Physical Activity in Treating Fatigue in Patients With Advanced Cancer

> **NCT02940223** · PHASE2 · TERMINATED · sponsor: **M.D. Anderson Cancer Center** · enrollment: 2 (actual)

## Conditions studied

- Advanced Malignant Neoplasm
- Fatigue

## Interventions

- **DRUG:** Ethyl Icosapentate
- **BEHAVIORAL:** Exercise Intervention
- **BEHAVIORAL:** Exercise Intervention
- **OTHER:** Laboratory Biomarker Analysis
- **OTHER:** Placebo
- **BEHAVIORAL:** Quality-of-Life Assessment
- **OTHER:** Questionnaire Administration

## Key facts

- **NCT ID:** NCT02940223
- **Lead sponsor:** M.D. Anderson Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2017-03-16
- **Primary completion:** 2020-11-24
- **Final completion:** 2020-11-24
- **Target enrollment:** 2 (ACTUAL)
- **Why stopped:** PI is requesting termination (closure) of this study.
- **Last updated:** 2021-06-10

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02940223

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02940223, "Ethyl Icosapentate and Physical Activity in Treating Fatigue in Patients With Advanced Cancer". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT02940223. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*